Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMN 351 open-label extension in Duchenne muscular dystrophy
NL-OMON59147Phase 2Recruiting
- Sponsor
- BioMarin Pharmaceutical
- Start
- Apr 2026
- Modality
- Gene Therapies, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of BMN-351 in Duchenne muscular dystrophy (DMD), sponsored by BioMarin Pharmaceutical. Primary endpoints: Incidence of adverse events, serious adverse events, and adverse events of special interest, Physical examination and 3 more. Started Apr 2026; status: recruiting.
02
Drugs
BMN-351
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NL-OMON59147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59147.